Results 191 to 200 of about 13,796 (248)

SAKK 35/14 randomized trial of rituximab with or without ibrutinib for patients with untreated follicular lymphoma

British Journal of Haematology, EarlyView.
Summary The randomized phase II SAKK 35/14 trial, conducted by the Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG), compared efficacy and safety of rituximab (375 mg/m2 intravenously for 4 weeks followed by maintenance every 2 months for 24 months) plus placebo (arm A) versus the same schedule of rituximab plus ...
Maria Cristina Pirosa, Marianne Brodtkorb, Sämi Schär, Björn E. Wahlin, Micaela Hernberg, Michael Pedersen, Anastasios Stathis, Thilo Zander, Urban Novak, Thorsten Zenz, Natalie Fischer, Fatime Krasniqi, Felicitas Hitz, Ann‐Sofie Johansson, David Löfgren, Peter Albert Meyer, Anne Turid Bjørnevik, Giulio Sartori, Stefanie Hayoz, Andrea Fuhrer, Luzia Steiner, Francesco Bertoni, Luca Ceriani, Stefan Dirnhofer, Emanuele Zucca, Bjørn Østenstad   +25 more
wiley   +1 more source

A proactive large platelet-driven screening strategy for the early recognition of MYH9-related disease: a Chinese prospective cohort study. [PDF]

Res Pract Thromb Haemost
Chen W, Arif AR, Ding Y, Wang L, Cai L, Arif M, Xue M, Mei H, Wang Y.   +8 more
europepmc   +1 more source

Early-Onset Mucocutaneous Findings and Isolated Progressive Thrombocytopenia in a Child With a DKC1 A353V Variant. [PDF]

Clin Case Rep
Kasapoğlu H, Yılmaz AT, Akbeyaz BB, Çalışkan N, Ay Y.   +4 more
europepmc   +1 more source

Immune Thrombocytopenia Purpura Versus Inherited Thrombocytopenia in Adults

The Hematologist, 2019
openaire   +1 more source

Case Report: Hematopoietic stem cell transplantation for refractory chronic immune thrombocytopenia in a child. [PDF]

Front Immunol
Liu F, Li H, Gu Y, Han Y, Ding G, Zhao Y, Zhang X, Li X, Feng H, Gong Y, Wang H.   +10 more
europepmc   +1 more source

A phase IIa study of the anti‐PD‐L1 antibody avelumab in relapsed/refractory PTCL: The AVAIL‐T trial

British Journal of Haematology, EarlyView.
The AVAIL‐T study, the first evaluation of programmed death ligand 1 (PD‐L1) blockade in relapsed/refractory peripheral T‐cell lymphomas (PTCL), demonstrated limited single agent activity with durable responses seen in a minority. Circulating tumour DNA revealed distinct mutational dynamics and mass cytometry identified perturbed T‐cell subsets ...
Matthew J. Ahearne, Matthew A. Timmins, Charlotte Gaskell, Aimee Jackson, Clare Morland, Sonia Fox, Louise Hopkins, Nadia Nawaz, Susann Lehmann, Marc Wadsley, Caroline Cowley, Jacqueline Shaw, Naeem Khan, Nagesh Kalakonda, Christopher Trethewey, Ram Malladi, Paul Fields, Dima El Sharkawi, Michael Quinn, Nimish Shah, Andrew Davies, Kim Linton, Pam McKay, Rod Johnson, Simon D. Wagner, David Lewis, Graham P. Collins, Christopher P. Fox, Kate Cwynarski   +28 more
wiley   +1 more source

Pregnancy in Lysinuric Protein Intolerance Complicated by Immune Dysregulation and Severe Thrombocytopenia. [PDF]

JIMD Rep
McCarron EP, Hill M, Lomas A, Elliott V, Walkinshaw E, Bonnett T, Kuet KP, Tattersall R, Mapplebeck C.   +8 more
europepmc   +1 more source

Prospective phase I study of nivolumab to promote graft‐versus‐tumour in relapsed or refractory haematological malignancy post allogeneic haematopoietic stem cell transplantation

British Journal of Haematology, EarlyView.
Baseline immunophenotype and gene expression predict suitability for salvage nivolumab in patients with relapsed/refractory haematological malignancy. Summary Allogeneic haematopoietic stem cell transplantation (alloHSCT) relies on donor‐derived T cells to mediate the graft‐versus‐tumour (GVT) effect, but relapse may result from impaired immune ...
Trung Q. Ngo, Eric Wong, Joanne E. Davis, Mandy Ludford‐Menting, Jessica Klass, Sara K. Dohrmann, Rachel Koldej, David Ritchie   +7 more
wiley   +1 more source

Sea-blue histiocytosis and thrombocytopenia successfully treated with an mTORC1 inhibitor: a case report. [PDF]

Ann Hematol
Li H, Ma J, Hu Y, Ma J, Liu G, Wei Y, Yang C, Wu R.   +7 more
europepmc   +1 more source